Key facts
- Aqtual’s last known valuation is $68.4M (Jul 2025).
- It has raised $51.7M; the latest was Later Stage VC ($31.0M) in Jul 2025.
- Notable investors include BOLD Capital Partners, Manta Ray Ventures, Genoa Ventures, BOLD Longevity Growth, Yu Galaxy — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Aqtual
- ·The full record, as it builds
Funding rounds
No funding rounds for Aqtual are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aqtual
Developer of a novel analytical platform designed for cancer drug treatment. The company's platform captures disease molecular signals in circulating deoxyribonucleic acid to improve sensitivity, specificity and timing in diagnostic and disease management, enabling patients to get personalized cancer treatment.
- Sector
- Healthcare
- HQ
- Hayward, CA, United States
- Founded
- 2019
- Employees
- 36
- Website
- aqtual.com/
- Ownership
- Privately Held (backing)
Aqtual doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aqtual shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aqtual in its N-PORT filings yet. We sweep new filings monthly.